Tissue plasminogen activator (tPA) is the only FDA-approved drug for acute stroke treatment; however, only <5% of patients with ischemic stroke receive tPA because it has the potential to cause hemorrhagic transformation (Chalouhi et al., 2013; Bruch et al., 2019; Kuo et al., 2020). Here, PLAT is linked to ischemic stroke.